UNS - Unilife Corporation

[Sean K]

The payments came from upfront payments which are scheduled to continue through the first half of the year at that time the hikma production is due to ramp up . This is also what he has been saying for some time and is so far delivering on
I expect the atm will be tapped out either end of march or early april . More likely early april. I do not expect a secondary offering to occur untill the planned second factory in europe(Ireland ?) is about to be built about three years a way.

So, do you think they've sold any syringes yet? All the money they're getting seems to be 'up front' payments, not 'sales'. It's a bit opaque, to say the least. Especially when they keep chiming on about 'confidentiality agreements'. No one knows what they're selling really.

 

[pacestick]

Actually I know they have sold some syringes. They have sold syringes to the unknown company that began to take commercial supply last july and is due tounch their product in the unifill syringe this july but it was always a small order . The larhger orders kick off this july when the hikma deal starts its ramp up by january the present production line will not be able to handle the demand for hikma sanofi the unknown poharma and other samples that go out for testing . There fore I expect a order to be placed for another production line before easter

 

[Sean K]

Half yearly out today.

$4.3m left in the bank.
Losing about $14m a quarter, so, hmmm.
Accumulated deficit (dilution) $263m. ouch
Company continues to hand out massive incentive options based on no sales.

Any idea what this means?

Mortgage Loans

In October 2010, Unilife Cross Farm LLC, a wholly owned subsidiary of the Company, (“Cross Farm”) entered into a loan agreement with Metro Bank (“Metro”), pursuant to which Metro provided Cross Farm with two mortgage loans in the amounts of $14.25 million and $3.75 million. The proceeds received were used to finance the purchase of land and construction of the Company’s corporate headquarters and manufacturing facility in York, Pennsylvania.

During construction, Cross Farm paid only interest on both term loans at the Prime Rate plus 1.50% per annum, with a floor of 4.50% per annum. Subsequent to construction, Cross Farm is paying principal and interest on both term loans, with interest at a fixed rate of 6.00%. The weighted average interest rate on both term notes was 6.00% during the six months ended December 31, 2013 and the year ended June 30, 2013.

The loan agreement contains certain customary covenants, including the maintenance of a Debt Service Reserve Account in the amount of $2.4 million, classified as restricted cash on the consolidated balance sheet, which will remain in place until Cross Farm and Metro agree on the financial covenants. The terms of the loan agreement allow the Company to use the Debt Service Reserve Account to pay monthly debt service on the mortgage loans, so long as the balance in the account is at least $1.6 million and is replenished to $2.4 million every six months. The Company was in compliance with its debt covenants as of December 31, 2013. However, there can be no assurance that the Company will be able to maintain the Debt Service Reserve Account balance for a period of 12 months from December 31, 2013. Cross Farm may prepay the loan without penalty. The U.S. Department of Agriculture has guaranteed $10.0 million of the loans.

In connection with the two mortgage loans and other bank term loans, the Company has given Metro Bank a lien on substantially all of the Company’s assets except for the Company’s intellectual property and certain other assets that are subject to other third party liens.

 

[pacestick]

Unilife Secures $60 Million Debt Financing with OrbiMed Advisors



YORK, Pa., March 13, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today announced that it has entered into a $60 million debt financing agreement with an affiliate of OrbiMed ("OrbiMed").

$40 million was funded to Unilife at the closing of the deal. Provided the Company is in compliance with the terms of the agreement, two additional tranches of $10 million each will be provided to Unilife in December 2014 and June 2015.

During the six year term of the agreement, Unilife will make interest-only payments to OrbiMed currently calculated at a rate of 10.25% per annum, with the principal to be repaid by March 12, 2020 ("Maturity Date"). OrbiMed will also receive a tiered royalty payment based on net sales generated by Unilife during each fiscal year of the agreement. The maximum royalty rate is 2.75% of annual net sales. The royalty rate decreases as annual net sales increases. Total royalties paid to OrbiMed under the agreement are capped as Unilife has the option to buy out the royalty payment, which is at a reduced amount at any time on or before the fourth anniversary of the agreement. No equity or warrants were or will be issued as part of this agreement.

Mr. Alan Shortall, Chairman and CEO of Unilife, said: "OrbiMed is one of the premier healthcare investors in the world. With OrbiMed and their independent advisors having conducted extensive due diligence into all aspects of our business, including our products, IP and commercial pipeline, we believe this agreement represents a significant endorsement of Unilife. In particular, I believe OrbiMed's decision to accept a small share of our future net sales highlights their confidence in our business model and future growth.

"This $60 million commitment provides us with the necessary capital to drive business growth as we bring several large contracts with existing customers through to commercial rollout. Our decision to take only $40 million of the $60 million upfront will ensure we have the cash to support our operations while minimizing interest payments. I believe Unilife's growing base of customers will view our long-term partnership with OrbiMed as a positive development, as it further strengthens our business position and capacity to meet their future needs," Mr. Shortall concluded.

 

[Sean K]

Unilife Secures $60 Million Debt Financing with OrbiMed Advisors



YORK, Pa., March 13, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today announced that it has entered into a $60 million debt financing agreement with an affiliate of OrbiMed ("OrbiMed").

$40 million was funded to Unilife at the closing of the deal. Provided the Company is in compliance with the terms of the agreement, two additional tranches of $10 million each will be provided to Unilife in December 2014 and June 2015.

During the six year term of the agreement, Unilife will make interest-only payments to OrbiMed currently calculated at a rate of 10.25% per annum, with the principal to be repaid by March 12, 2020 ("Maturity Date"). OrbiMed will also receive a tiered royalty payment based on net sales generated by Unilife during each fiscal year of the agreement. The maximum royalty rate is 2.75% of annual net sales. The royalty rate decreases as annual net sales increases. Total royalties paid to OrbiMed under the agreement are capped as Unilife has the option to buy out the royalty payment, which is at a reduced amount at any time on or before the fourth anniversary of the agreement. No equity or warrants were or will be issued as part of this agreement.

Mr. Alan Shortall, Chairman and CEO of Unilife, said: "OrbiMed is one of the premier healthcare investors in the world. With OrbiMed and their independent advisors having conducted extensive due diligence into all aspects of our business, including our products, IP and commercial pipeline, we believe this agreement represents a significant endorsement of Unilife. In particular, I believe OrbiMed's decision to accept a small share of our future net sales highlights their confidence in our business model and future growth.

"This $60 million commitment provides us with the necessary capital to drive business growth as we bring several large contracts with existing customers through to commercial rollout. Our decision to take only $40 million of the $60 million upfront will ensure we have the cash to support our operations while minimizing interest payments. I believe Unilife's growing base of customers will view our long-term partnership with OrbiMed as a positive development, as it further strengthens our business position and capacity to meet their future needs," Mr. Shortall concluded.

This is a very smart investment by OrbiMed. Look, it's probably more complicated than this, but 10% PA? On what? Nice. Who gets that these days? And, in 7 years, UNS have to pay the principle back. $60m? What happens when they default? No detail of that little gem. I think OrbMed is probably short UNS.

 

[pacestick]

Unilife Responds to Malicious Blogs

YORK, Pa., April 22, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today issued a response on behalf of its shareholders in relation to a series of malicious blogs containing false and misleading information published over recent months by short sellers on the Seeking Alpha website.

Unilife has requested that the SEC investigate these short sellers and their associates for stock manipulation and illicit gains. Unilife categorically refutes any allegations of wrong-doing by the Company, its directors, officers and management. In particular, Unilife would like to address the following:

Most of these allegations relate to a wrongful termination lawsuit by a former employee who was terminated "for cause," and the related SEC review of the matter, which Unilife first disclosed more than 18 months ago and has repeated in subsequent regulatory filings and earnings calls.

Unilife has refuted these allegations, declined a settlement offer by the plaintiff, and expects to prevail should the case proceed to trial. Unilife has co-operated fully with the SEC in its review, provided extensive information, and responded to all questions. Unilife does not believe that there are any grounds for any action to be taken against the Company.

Unilife has never paid anyone to publish articles about it. No officer has ever sold Unilife stock since the Company listed on NASDAQ in 2010, with the CEO and COO having purchased in excess of $4 million in Unilife stock in recent years. The CFO's departure was not due to a resignation but part of a long-term succession plan. Mr. Shortall has never been a director or officer of a Company that has failed, or gone bankrupt. Unilife has successfully been through numerous due diligence processes conducted by multiple global pharmaceutical customers, investors, analysts, financial auditors and regulatory bodies. By way of example, Unilife last month completed a $60 million non-dilutive debt financing with OrbiMed, the world's largest healthcare-dedicated investor. OrbiMed, together with its outside experts and advisors, undertook extensive due diligence over several months into all aspects of the Unilife business including its products, staff, patents, contracts and commercial pipeline.

Unilife encourages the SEC to act quickly to address these illegal actions by the relevant short sellers and their associates. Unilife's team, which is now more than 190 strong and consisting of some of the most highly qualified industry experts, will continue to drive the business, serve existing and new customers and build shareholder value.

About Unilife Corporation
Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor Contacts (US):

Analyst Enquiries

Investor Contacts (AUS)

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-896-1215 / 212-896-1250
P: + 1 415-202-5678
P: + 61 2 8346 6500

SOURCE Unilife Corporation

Unilife Corporation
250 Cross Farm Road , York, PA 17406

http://www.prnewswire.com/news-releases/unilife-responds-to-malicious-blogs-256264011.html

 

[Sean K]

Pacestick, I agree that there are sections of the US stock market commentary who are short UNS and then pick on the negative fundamentals of the stock, and it's CEO. They do disclaim that too. But, there's probably an equal number of brokers who give glowing reviews of UNS, who have been involved in placements and funding and also have a vested interest.

My best guess continues to be that they will not get enough market share, nor be able to produce enough product at the right price, to compete. The bottom line is that they seem to be making plastic things not too much better, if at all, but more expensive, than the other guys...

 

[pacestick]

well some big companies are paying millions just for the right to buy the plastic bits in the near future

highlights from the 4c below



For this consolidated statement of cash flow for the Third Fiscal Quarter of 2014, I would like to highlight the following

• Total cash receipts from customers for the Current Quarter were $10.9 million, an increase of $10.8 million compared to the same quarter in Fiscal Year 2013.

• Total cash receipts from customers for the Fiscal Year to Date (nine months ended March 31, 2014) were $22.6 million, an increase of $21.5 million compared to the same quarter in Fiscal Year 2013.

• Unilife generated cash receipts from ten ongoing customer programs during the Fiscal Year to Date, with the majority of these programs generating cash receipts during the Current Quarter.

• Total cash at the end of the Current Quarter (March 31, 2014) was $39.8 million, an increase of $30.1 million compared to the same quarter in Fiscal Year 2013. Compared to the end of the Second Fiscal Quarter of 2014 (December 31, 2013), total cash at the end of the Current Quarter increased by $33.0 million.

• Cash flows relating to staff costs, research and development, and interest payments for the Current Quarter were stable
compared to the Second Fiscal Quarter of 2014.

• Net investing cash flows for the Current Quarter were $1.6 million, an increase of $1.0 million compared to the Second Fiscal

Quarter of 2014, largely due to an increase in equipment purchases relating to production scale-up.

• Total net operating cash outflow relating to operating activities for the Current Quarter was $2.0 million, compared to a cash outflow of $10.2 million for the same quarter in Fiscal Year 2013, a reduction of $8.2 million or 80%.

 

[pacestick]

Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers

Revenue for fiscal year 2014 anticipated to be at the high end of the $12 million to $15 million guidance range
Unifill commercial sales to commence this fiscal quarter and accelerate through FY2015 and FY2016
First commercial Unifill Finesse manufacturing line operational with additional lines on order and in progress

YORK, Pa., July 30, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced an acceleration of investments in manufacturing capacity, R&D, and facilities in response to increasing demand from pharmaceutical and biotechnology companies for its products and services. During the fourth quarter of fiscal year 2014, the Company invested approximately $16 million in capital expenditures and R&D above normal quarterly investments.

Mr. Alan Shortall Chairman and CEO of Unilife said, "We are scaling-up our operational capacity to support increasing demand from existing and new pharmaceutical customers. Some of this expansion is occurring ahead of schedule as customers seek to accelerate their commercial launch timelines under existing contracts, and we commence a multitude of new programs for the customization and supply of products from across our broad portfolio. This resulted in a surge of capital expenditure and R&D during the fourth quarter of fiscal year 2014. We have elected to capitalize on these opportunities by making this one-time increase in expenditure during the fourth quarter of fiscal year 2014.

"We begin fiscal year 2015 with 12 active programs from 11 customers, with additional contracts in the final stages of formalization. Cash receipts and revenue are expected to increase during fiscal year 2015 via a diversified and expanding base of customers and programs. We expect that ongoing investments in capital equipment and R&D during fiscal year 2015 will be funded by customer payments under existing and upcoming programs, our long-term debt financing agreement with OrbiMed and current cash on hand. In addition, we have access to $12.8 million under the ATM ("At the Market") facility with Cantor Fitzgerald. As we take receipt of additional manufacturing lines where we have made large upfront payments, we may also secure capital equipment financing, where appropriate, to support the continued scale-up of our production capabilities," Mr. Shortall continued.

Unilife remains on schedule to commence the commercial sale of three separate Unifill product lines to multiple customers between now and the middle of fiscal year 2015. Commercial sales of Unifill ® syringes are scheduled to commence during the current first fiscal quarter of 2015 utilizing an existing commercial manufacturing line. Commercial sales of the Unifill Finesse ® and the Unifill Nexus are scheduled to commence during the middle of the fiscal year on additional manufacturing lines that are either in the process of being configured, or are now operational and in the process of being qualified.

Unifill products sold in fiscal year 2015 are expected to be used by customers for a range of purposes including compatibility studies and filling and packaging validation prior to the expected commercial launch of target injectable therapies. In addition to generating revenue via the commercial sale of Unifill products, Unilife expects to receive upfront and milestone-based payments from various customers during fiscal year 2015.

Unilife also invested in an expansion of its manufacturing capacity for wearable injectors during the fourth quarter of fiscal 2014 in response to accelerating customer demand for programs that are either underway or about to commence. This investment by Unilife in its platform of wearable injectors has enabled the Company to provide customers with a broader range of product configurations utilizing a manufacturing line with key automated processes earlier than originally anticipated to support drug stability studies, feasibility programs, filling line validation, human clinical trials and human factors studies. Unilife also invested in the expansion of its manufacturing capabilities for additional product platforms across its broad portfolio of injectable drug delivery systems.

Unilife has completed a reconfiguration of its existing cleanrooms at its production facility in York, PA to accommodate new manufacturing lines for its Unifill products and wearable injectors that will support scheduled customer demand during fiscal year 2015. Unilife is also continuing the process of building new cleanrooms that will double the size of its cleanroom space at this facility to support the continued scale-up in production for existing and upcoming customer programs. This extra cleanroom space is expected to come on line in stages to support the planned arrival of additional manufacturing lines and equipment.

The Company has also increased its cross-functional R&D teams of engineers and other staff that are dedicated to servicing existing and prospective customers, with more than 200 staff now employed across the business. Part of the increase in R&D expenditure during fiscal year 2014 related to the supply of products and components to current and prospective pharmaceutical companies to support evaluation processes and user studies that are typically undertaken prior to the anticipated signing of contracts.

A video of the Unifill Finesse manufacturing line in operation and in the process of being qualified at Unilife's facility in York, PA can be viewed on the homepage of the Unilife website at www.unilife.com.

Fiscal Year 2014 Outlook

Mr. Shortall continued: "We are pleased with the trajectory of our business so far. We have invested in R&D during the last three years to build a critical mass in product range, industry expertise and operational capabilities. That investment is now generating revenue at an attractive growth rate. We are pleased to refine our full year revenue guidance for fiscal year 2014 to the high end of the $12 million to $15 million range that we had guided previously.

"We anticipate full year fiscal 2015 revenue to show strong growth over fiscal year 2014. We expect to moderate our investment in R&D during fiscal year 2015 while keeping SG&A largely flat. The increasing revenue and decrease in R&D investment is expected to allow us to continue narrowing our operating income loss and operating cash flow loss during fiscal year 2015. As the mix of the revenue expands beyond fees and shifts toward commercial sales, we expect to naturally increase our investment in capital expenditure. Beyond our current plans, we do not anticipate any additional increase in capital expenditure during fiscal year 2015," Mr. Shortall concluded.

About Unilife

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, intraocular delivery systems and novel devices. Each of these innovative, differentiated technology platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, Pennsylvania. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor / PR Contacts (US):


Analyst Enquiries


Investor Contacts (Australia)

Todd Fromer / Garth Russell


Leigh Salvo


Jeff Carter

KCSA Strategic Communications


Westwicke Partners


Unilife Corporation

P: + 1 212-682-6300


P: + 1 415-513-1281


P: + 61 2 8346 6500

 

[Sean K]

Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers

Revenue for fiscal year 2014 anticipated to be at the high end of the $12 million to $15 million guidance range
Unifill commercial sales to commence this fiscal quarter and accelerate through FY2015 and FY2016
First commercial Unifill Finesse manufacturing line operational with additional lines on order and in progress

YORK, Pa., July 30, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced an acceleration of investments in manufacturing capacity, R&D, and facilities in response to increasing demand from pharmaceutical and biotechnology companies for its products and services. During the fourth quarter of fiscal year 2014, the Company invested approximately $16 million in capital expenditures and R&D above normal quarterly investments.

Mr. Alan Shortall Chairman and CEO of Unilife said, "We are scaling-up our operational capacity to support increasing demand from existing and new pharmaceutical customers. Some of this expansion is occurring ahead of schedule as customers seek to accelerate their commercial launch timelines under existing contracts, and we commence a multitude of new programs for the customization and supply of products from across our broad portfolio. This resulted in a surge of capital expenditure and R&D during the fourth quarter of fiscal year 2014. We have elected to capitalize on these opportunities by making this one-time increase in expenditure during the fourth quarter of fiscal year 2014.

"We begin fiscal year 2015 with 12 active programs from 11 customers, with additional contracts in the final stages of formalization. Cash receipts and revenue are expected to increase during fiscal year 2015 via a diversified and expanding base of customers and programs. We expect that ongoing investments in capital equipment and R&D during fiscal year 2015 will be funded by customer payments under existing and upcoming programs, our long-term debt financing agreement with OrbiMed and current cash on hand. In addition, we have access to $12.8 million under the ATM ("At the Market") facility with Cantor Fitzgerald. As we take receipt of additional manufacturing lines where we have made large upfront payments, we may also secure capital equipment financing, where appropriate, to support the continued scale-up of our production capabilities," Mr. Shortall continued.

Unilife remains on schedule to commence the commercial sale of three separate Unifill product lines to multiple customers between now and the middle of fiscal year 2015. Commercial sales of Unifill ® syringes are scheduled to commence during the current first fiscal quarter of 2015 utilizing an existing commercial manufacturing line. Commercial sales of the Unifill Finesse ® and the Unifill Nexus are scheduled to commence during the middle of the fiscal year on additional manufacturing lines that are either in the process of being configured, or are now operational and in the process of being qualified.

Unifill products sold in fiscal year 2015 are expected to be used by customers for a range of purposes including compatibility studies and filling and packaging validation prior to the expected commercial launch of target injectable therapies. In addition to generating revenue via the commercial sale of Unifill products, Unilife expects to receive upfront and milestone-based payments from various customers during fiscal year 2015.

Unilife also invested in an expansion of its manufacturing capacity for wearable injectors during the fourth quarter of fiscal 2014 in response to accelerating customer demand for programs that are either underway or about to commence. This investment by Unilife in its platform of wearable injectors has enabled the Company to provide customers with a broader range of product configurations utilizing a manufacturing line with key automated processes earlier than originally anticipated to support drug stability studies, feasibility programs, filling line validation, human clinical trials and human factors studies. Unilife also invested in the expansion of its manufacturing capabilities for additional product platforms across its broad portfolio of injectable drug delivery systems.

Unilife has completed a reconfiguration of its existing cleanrooms at its production facility in York, PA to accommodate new manufacturing lines for its Unifill products and wearable injectors that will support scheduled customer demand during fiscal year 2015. Unilife is also continuing the process of building new cleanrooms that will double the size of its cleanroom space at this facility to support the continued scale-up in production for existing and upcoming customer programs. This extra cleanroom space is expected to come on line in stages to support the planned arrival of additional manufacturing lines and equipment.

The Company has also increased its cross-functional R&D teams of engineers and other staff that are dedicated to servicing existing and prospective customers, with more than 200 staff now employed across the business. Part of the increase in R&D expenditure during fiscal year 2014 related to the supply of products and components to current and prospective pharmaceutical companies to support evaluation processes and user studies that are typically undertaken prior to the anticipated signing of contracts.

A video of the Unifill Finesse manufacturing line in operation and in the process of being qualified at Unilife's facility in York, PA can be viewed on the homepage of the Unilife website at www.unilife.com.

Fiscal Year 2014 Outlook

Mr. Shortall continued: "We are pleased with the trajectory of our business so far. We have invested in R&D during the last three years to build a critical mass in product range, industry expertise and operational capabilities. That investment is now generating revenue at an attractive growth rate. We are pleased to refine our full year revenue guidance for fiscal year 2014 to the high end of the $12 million to $15 million range that we had guided previously.

"We anticipate full year fiscal 2015 revenue to show strong growth over fiscal year 2014. We expect to moderate our investment in R&D during fiscal year 2015 while keeping SG&A largely flat. The increasing revenue and decrease in R&D investment is expected to allow us to continue narrowing our operating income loss and operating cash flow loss during fiscal year 2015. As the mix of the revenue expands beyond fees and shifts toward commercial sales, we expect to naturally increase our investment in capital expenditure. Beyond our current plans, we do not anticipate any additional increase in capital expenditure during fiscal year 2015," Mr. Shortall concluded.

About Unilife

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, intraocular delivery systems and novel devices. Each of these innovative, differentiated technology platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, Pennsylvania. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor / PR Contacts (US):


Analyst Enquiries


Investor Contacts (Australia)

Todd Fromer / Garth Russell


Leigh Salvo


Jeff Carter

KCSA Strategic Communications


Westwicke Partners


Unilife Corporation

P: + 1 212-682-6300


P: + 1 415-513-1281


P: + 61 2 8346 6500

I note that in this statement they claim to have about $12m in the ATM facility (that was never supposed to be touched, but has been used to pay the bills) but only a couple of weeks later they announced that it had been completely used up. LOL

 

[pacestick]

September 9, 2014
Unilife Corporation Announces Financial Results For the Fourth Quarter and Full Fiscal Year 2014

YORK, Pa., Sept. 9, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the fiscal fourth quarter and full fiscal year ending June 30, 2014.

Recent Highlights

Revenue for the Full Fiscal Year of 2014 was $14.7 million, an increase of approximately $12 million or over 400% compared to the prior year. Deferred revenue, which is cash that has been collected and is expected to be recognized within the coming 24 months, for the Full Fiscal Year of 2014 increased to $13.3 million.
Cash receipts from customers were $23.7 million for the Full Fiscal Year of 2014, an increase of $22.5 million compared to the prior year.
The net operating cash flow loss was narrowed by 20% over the year before, despite a significant increase in R&D investments. Over half of the Company's total annual operating expenses were invested in R&D during the Full Fiscal Year of 2014.
At the end of the fourth quarter of Fiscal Year 2014, Unilife had 12 active customer programs, an increase of two programs since the end of the prior quarter, across all six of its product platforms.
Since July 1, 2014, Unilife has commenced commercial sales of the Unifill ® syringe utilizing an existing commercial manufacturing line. Commercial sales of other products from the Unifill family, including the Unifill Finesse ® and the Unifill Nexus™, are scheduled to commence during the middle of the 2015 fiscal year on additional manufacturing lines that are either in the process of being configured or are now operational and in the process of being qualified.

Mr. Alan Shortall, Chairman and CEO of Unilife, commented: "Fiscal 2014 was a year of rapid growth in revenue, customers, supply agreements and production capabilities. Having made significant investments in R&D during the last three years, we have achieved a critical mass in product range, capabilities and industry expertise. Those investments are now generating revenue at an attractive growth rate as we enter into and execute upon supply agreements with a growing number of pharmaceutical customers."

"During Fiscal Year 2015, we look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, we expect to increase capital expenditures in response to growing customer demand while moderating our investments in R&D and keeping SG&A largely stable. We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line. Based upon current cash on hand including the recently completed ATM, along with scheduled payments under existing and imminent agreements, we feel confident that we will have sufficient cash to offset our full year operating activities for fiscal 2015," Mr. Shortall concluded.

Financial Results for the Full Fiscal Year 2014

Revenue for the Full Fiscal Year of 2014 was $14.7 million, compared to $2.7 million for the same period in 2013. Deferred revenue increased to $13.3 million as of June 30, 2014. The Company's net loss for the Full Fiscal Year of 2014 was $57.9 million, or $0.59 per share, compared to a net loss of $63.2 million, or $0.78 per share, for fiscal year 2013.

Adjusted net loss for the Full Fiscal Year of 2014 was $38.8 million, or $0.40 per share, compared to $38.0 million or $0.47 per share for the prior year. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization, interest expense and the change in fair value of financial instruments.

Unilife reported $10.8 million in total cash and restricted cash at the end of Fiscal Year 2014, which ended on June 30, 2014. This does not include $12.4 million in net proceeds generated through the completion of our ATM facility in August 2014, or other cash receipts generated by customers since July 1, 2014.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014, (Wednesday, September 10, 2014 at 6:30 a.m. AEST), to review the Company's financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Non-GAAP Financial Measures

U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.



General: UNIS-G


Investor Contacts (US):


Analyst Enquiries


Investor Contacts (Australia)

Todd Fromer / Garth Russell


Leigh Salvo


Jeff Carter

KCSA Strategic Communications


Westwicke Partners


Unilife Corporation

P: + 1 212-682-6300


P: + 1 415-513-1281


P: + 61 2 8346 6500

 

[Sean K]

September 9, 2014
Unilife Corporation Announces Financial Results For the Fourth Quarter and Full Fiscal Year 2014

YORK, Pa., Sept. 9, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the fiscal fourth quarter and full fiscal year ending June 30, 2014.

Recent Highlights

Revenue for the Full Fiscal Year of 2014 was $14.7 million, an increase of approximately $12 million or over 400% compared to the prior year. Deferred revenue, which is cash that has been collected and is expected to be recognized within the coming 24 months, for the Full Fiscal Year of 2014 increased to $13.3 million.
Cash receipts from customers were $23.7 million for the Full Fiscal Year of 2014, an increase of $22.5 million compared to the prior year.
The net operating cash flow loss was narrowed by 20% over the year before, despite a significant increase in R&D investments. Over half of the Company's total annual operating expenses were invested in R&D during the Full Fiscal Year of 2014.
At the end of the fourth quarter of Fiscal Year 2014, Unilife had 12 active customer programs, an increase of two programs since the end of the prior quarter, across all six of its product platforms.
Since July 1, 2014, Unilife has commenced commercial sales of the Unifill ® syringe utilizing an existing commercial manufacturing line. Commercial sales of other products from the Unifill family, including the Unifill Finesse ® and the Unifill Nexus™, are scheduled to commence during the middle of the 2015 fiscal year on additional manufacturing lines that are either in the process of being configured or are now operational and in the process of being qualified.

Mr. Alan Shortall, Chairman and CEO of Unilife, commented: "Fiscal 2014 was a year of rapid growth in revenue, customers, supply agreements and production capabilities. Having made significant investments in R&D during the last three years, we have achieved a critical mass in product range, capabilities and industry expertise. Those investments are now generating revenue at an attractive growth rate as we enter into and execute upon supply agreements with a growing number of pharmaceutical customers."

"During Fiscal Year 2015, we look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, we expect to increase capital expenditures in response to growing customer demand while moderating our investments in R&D and keeping SG&A largely stable. We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line. Based upon current cash on hand including the recently completed ATM, along with scheduled payments under existing and imminent agreements, we feel confident that we will have sufficient cash to offset our full year operating activities for fiscal 2015," Mr. Shortall concluded.

Financial Results for the Full Fiscal Year 2014

Revenue for the Full Fiscal Year of 2014 was $14.7 million, compared to $2.7 million for the same period in 2013. Deferred revenue increased to $13.3 million as of June 30, 2014. The Company's net loss for the Full Fiscal Year of 2014 was $57.9 million, or $0.59 per share, compared to a net loss of $63.2 million, or $0.78 per share, for fiscal year 2013.

Adjusted net loss for the Full Fiscal Year of 2014 was $38.8 million, or $0.40 per share, compared to $38.0 million or $0.47 per share for the prior year. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization, interest expense and the change in fair value of financial instruments.

Unilife reported $10.8 million in total cash and restricted cash at the end of Fiscal Year 2014, which ended on June 30, 2014. This does not include $12.4 million in net proceeds generated through the completion of our ATM facility in August 2014, or other cash receipts generated by customers since July 1, 2014.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014, (Wednesday, September 10, 2014 at 6:30 a.m. AEST), to review the Company's financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Non-GAAP Financial Measures

U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.



General: UNIS-G


Investor Contacts (US):


Analyst Enquiries


Investor Contacts (Australia)

Todd Fromer / Garth Russell


Leigh Salvo


Jeff Carter

KCSA Strategic Communications


Westwicke Partners


Unilife Corporation

P: + 1 212-682-6300


P: + 1 415-513-1281


P: + 61 2 8346 6500

Any idea where the revenue came from RSM?

Revenue up 400%!

Share price down 60% since April

 

[pacestick]

Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi

Unilife to be the sole provider of wearable injectors for all of Sanofi's applicable large dose volume drugs

YORK, Pa., Oct. 6, 2014 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, announced today the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Additionally the agreement will allow Sanofi to make Unilife's wearable injectors available to its partners for use with applicable molecules under joint collaborations.

Unilife has granted Sanofi non-exclusive access to its wearable injector technology during the agreement. Unilife maintains the right to enter into supply agreements with other pharmaceutical companies for the use of its wearable injectors, so long as Sanofi's non-exclusive access is preserved. Sanofi also has the option to extend the agreement for additional periods. In addition to an upfront payment and device sales, Unilife anticipates it will receive approximately $50 million from customization programs relating to Sanofi molecules and indications. Additional revenue is also expected from customization programs conducted under joint collaborations with Sanofi partners. Unilife will begin to generate revenue from Sanofi this fiscal year from an upfront payment, customization programs and initial commercial sales of the devices to Sanofi. Unilife and Sanofi will also collaborate in the development of other new technologies that address additional unmet or emerging needs for the delivery of large dose volume biologics. Additional information will remain confidential at this time.

Mr. Alan Shortall, Chairman and Chief Executive Officer of Unilife said: "Unilife continues to advance our lead position in the fast-growing market for wearable injectors, a market which is expected to generate $8 billion in sales at an average $25 per unit by 2025. Based upon public information and industry forecasts, Unilife estimates that Sanofi has between 5 to 10 molecules that will be delivered in wearable injectors. With many pharmaceutical companies having up to a dozen large dose volume biologics that will each require an average of five million units per drug per year, our wearable injectors are poised to generate substantial revenue and growth moving forward. Additionally, we anticipate substantial incremental revenue will be generated from customization programs conducted under joint collaborations with Sanofi partners that choose to participate," Mr. Shortall concluded.

Unilife Platform of Wearable Injectors

The Precision-Therapy™ platform of disposable wearable injectors can be worn on the body of a patient during the subcutaneous administration of a large dose volume drug. Unilife's wearable injectors can be prefilled, pre-assembled and ready to use, with only three intuitive steps for a patient to peel off the label, stick the product onto the body and click a button to commence the injection of a drug (Peel, Stick and Click™). Unilife wearable injectors require no terminal sterilization, utilize standard materials in the primary drug container and are supplied for seamless integration with standard filling and packaging systems. Products can be pre-configured to administer a measured dose volume over a designated period of time, typically ranging between one and thirty minutes. Unilife wearable injectors utilize a Flexwear™ comfort catheter for patient comfort, and an on-body safety lock that prevents unintentional activation.

The Global Market for Wearable Injectors

Wearable injectors are prefilled, disposable devices that are worn on the body of a patient during the subcutaneous administration of a large volume dose of medication. The market for wearable injectors is poised to experience rapid growth over the coming decade due to a convergence of market trends including accelerating pharmaceutical investment in biologics requiring large volume doses, and the shift of healthcare treatment from healthcare facilities to safe, simple and convenient self-injection by patients. According to the independent market research report Large Volume Wearable Injectors published by Roots Analysis in September 2014, it is estimated that the market for wearable injectors will generate up to $8 billion in sales by 2025, with 181 biologics across 14 disease areas identified for use with wearable injectors. The average selling price for a wearable injector is estimated to be on average between $25 and $35 per unit.

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

General: UNIS-G

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Investor / PR Contacts (US):


Analyst Enquiries


Investor Contacts (Australia)

Todd Fromer / Garth Russell


Leigh Salvo


Jeff Carter

KCSA Strategic Communications


Westwicke Partners


Unilife Corporation

P: + 1 212-682-6300


P: + 1 415-513-1281


P: + 61 2 8346 650

Unilife Corporation
250 Cross Farm Road , York, PA 17406
Service provided by Shareholder.com

 

[Sean K]

Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi

Unilife to be the sole provider of wearable injectors for all of Sanofi's applicable large dose volume drugs

YORK, Pa., Oct. 6, 2014 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, announced today the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Additionally the agreement will allow Sanofi to make Unilife's wearable injectors available to its partners for use with applicable molecules under joint collaborations.

Unilife has granted Sanofi non-exclusive access to its wearable injector technology during the agreement. Unilife maintains the right to enter into supply agreements with other pharmaceutical companies for the use of its wearable injectors, so long as Sanofi's non-exclusive access is preserved. Sanofi also has the option to extend the agreement for additional periods. In addition to an upfront payment and device sales, Unilife anticipates it will receive approximately $50 million from customization programs relating to Sanofi molecules and indications. Additional revenue is also expected from customization programs conducted under joint collaborations with Sanofi partners. Unilife will begin to generate revenue from Sanofi this fiscal year from an upfront payment, customization programs and initial commercial sales of the devices to Sanofi. Unilife and Sanofi will also collaborate in the development of other new technologies that address additional unmet or emerging needs for the delivery of large dose volume biologics. Additional information will remain confidential at this time.

Mr. Alan Shortall, Chairman and Chief Executive Officer of Unilife said: "Unilife continues to advance our lead position in the fast-growing market for wearable injectors, a market which is expected to generate $8 billion in sales at an average $25 per unit by 2025. Based upon public information and industry forecasts, Unilife estimates that Sanofi has between 5 to 10 molecules that will be delivered in wearable injectors. With many pharmaceutical companies having up to a dozen large dose volume biologics that will each require an average of five million units per drug per year, our wearable injectors are poised to generate substantial revenue and growth moving forward. Additionally, we anticipate substantial incremental revenue will be generated from customization programs conducted under joint collaborations with Sanofi partners that choose to participate," Mr. Shortall concluded.

Unilife Platform of Wearable Injectors

The Precision-Therapy™ platform of disposable wearable injectors can be worn on the body of a patient during the subcutaneous administration of a large dose volume drug. Unilife's wearable injectors can be prefilled, pre-assembled and ready to use, with only three intuitive steps for a patient to peel off the label, stick the product onto the body and click a button to commence the injection of a drug (Peel, Stick and Click™). Unilife wearable injectors require no terminal sterilization, utilize standard materials in the primary drug container and are supplied for seamless integration with standard filling and packaging systems. Products can be pre-configured to administer a measured dose volume over a designated period of time, typically ranging between one and thirty minutes. Unilife wearable injectors utilize a Flexwear™ comfort catheter for patient comfort, and an on-body safety lock that prevents unintentional activation.

The Global Market for Wearable Injectors

Wearable injectors are prefilled, disposable devices that are worn on the body of a patient during the subcutaneous administration of a large volume dose of medication. The market for wearable injectors is poised to experience rapid growth over the coming decade due to a convergence of market trends including accelerating pharmaceutical investment in biologics requiring large volume doses, and the shift of healthcare treatment from healthcare facilities to safe, simple and convenient self-injection by patients. According to the independent market research report Large Volume Wearable Injectors published by Roots Analysis in September 2014, it is estimated that the market for wearable injectors will generate up to $8 billion in sales by 2025, with 181 biologics across 14 disease areas identified for use with wearable injectors. The average selling price for a wearable injector is estimated to be on average between $25 and $35 per unit.

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

General: UNIS-G

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Investor / PR Contacts (US):


Analyst Enquiries


Investor Contacts (Australia)

Todd Fromer / Garth Russell


Leigh Salvo


Jeff Carter

KCSA Strategic Communications


Westwicke Partners


Unilife Corporation

P: + 1 212-682-6300


P: + 1 415-513-1281


P: + 61 2 8346 650

Unilife Corporation
250 Cross Farm Road , York, PA 17406
Service provided by Shareholder.com

pacestick, you've been copy and pasting UNS PR releases for some time with no comment or analysis of your own. Do you have a comment, or your own analysis to add?

 

[galumay]

pacestick, you've been copy and pasting UNS PR releases for some time with no comment or analysis of your own. Do you have a comment, or your own analysis to add?

Probably worth reporting him if he does it again, its hardly in the spirit of a public forum and it adds no value. We seem to attract a few of these 'pumpers' that simply post pressers with no commentary or analysis, I know Joe has cleaned up a couple of them and Pacestick looks to be sailing close to the wind!

 

[Sean K]

Probably worth reporting him if he does it again, its hardly in the spirit of a public forum and it adds no value. We seem to attract a few of these 'pumpers' that simply post pressers with no commentary or analysis, I know Joe has cleaned up a couple of them and Pacestick looks to be sailing close to the wind!

pacestick has suffered a great deal the past couple of years. UNS has been a turkey, with failed promises over a several years, if you add in the business's previous incarnations. The recent earnings result was down on forecast, but I'm still amazed they've secured any income. The past several years has all been up front / trial cash and going to the market continually. They've taken 100s of millions from the market to get to making, what? $3m. And, where did that come from anyway? You will never know because this company hides behind commercial-in-confidence without failure. With-out-failure. For all we know, UNS is buying their own stock just to make it look like they're selling their own plastic.

 

[Sean K]

I'm a bit concerned that old pacestick isn't posting. He should be happy that this has crawled off the carpet and seems to have some life. Was that a bottom at 30 cents? Should be good support now between 40 and 50, but due to their business being suspect, anything could happen. Another law suite anyone? How about some detail on the contracts in the pipeline. If I hear 'game changing' about some nicely presented plastic again, with no sales or profit forecasts, you'll know about it. Looks like the shorters are still in the game to me.

 

[Sean K]

Getting up around the 90c mark which is encouraging for long term speculators. Almost back to where it was 5 years ago. Recently recruited a marketing guy from Intel. Intel sells what? Anyway, back to the real story, does anyone have a PnL from the last 5 years stating where their revenue comes from?

 

[notting]

See something I don't think I've seen before, up 60% yesterday down 40% from yesterdays high.
Now that's a traders stock!
Time to bug the board room so we can front run the next announcement. What will it do Monday? :bounce:

 

[notting]

129% is that all you can give me in a day? Come on!
Nothing like a tie up contract with a US company on the table.